Literature DB >> 22044162

New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists.

Jenni Küblbeck1, Johanna Jyrkkärinne, Ferdinand Molnár, Tiina Kuningas, Jayendra Patel, Björn Windshügel, Tapio Nevalainen, Tuomo Laitinen, Wolfgang Sippl, Antti Poso, Paavo Honkakoski.   

Abstract

The human constitutive androstane receptor (CAR, NR1I3) is one of the key regulators of xenobiotic and endobiotic metabolism. The unique properties of human CAR, such as the high constitutive activity and the complexity of signaling, as well as the lack of functional and predictive cell-based assays to study the properties of the receptor, have hindered the discovery of selective human CAR ligands. Here we report a novel human CAR inverse agonist, 1-[(2-methylbenzofuran-3-yl)methyl]-3-(thiophen-2-ylmethyl) urea (S07662), which suppresses human CAR activity, recruits the corepressor NCoR in cell-based assays, and attenuates the phenytoin- and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO)-induced expression of CYP2B6 mRNA in human primary hepatocytes. The properties of S07662 are also compared with those of known human CAR inverse agonists by using an array of different in vitro and in silico assays. The identified compound S07662 can be used as a chemical tool to study the biological functions of human CAR and also as a starting point for the development of new drugs for various conditions involving the receptor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22044162     DOI: 10.1021/mp2003658

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  12 in total

1.  Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor.

Authors:  Wenwei Lin; Lei Yang; Sergio C Chai; Yan Lu; Taosheng Chen
Journal:  Eur J Med Chem       Date:  2015-12-15       Impact factor: 6.514

2.  Generation of Scalable Hepatic Micro-Tissues as a Platform for Toxicological Studies.

Authors:  Sara Darakhshan; Ali Bidmeshki Pour; Reza Kowsari-Esfahan; Massoud Vosough; Leila Montazeri; Mohammad Hossein Ghanian; Hossein Baharvand; Abbas Piryaei
Journal:  Tissue Eng Regen Med       Date:  2020-07-14       Impact factor: 4.169

Review 3.  Small-molecule modulators of the constitutive androstane receptor.

Authors:  Milu T Cherian; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05-15       Impact factor: 4.481

Review 4.  Small-molecule modulators of PXR and CAR.

Authors:  Sergio C Chai; Milu T Cherian; Yue-Ming Wang; Taosheng Chen
Journal:  Biochim Biophys Acta       Date:  2016-02-24

Review 5.  Targeting xenobiotic receptors PXR and CAR for metabolic diseases.

Authors:  Jie Gao; Wen Xie
Journal:  Trends Pharmacol Sci       Date:  2012-08-10       Impact factor: 14.819

Review 6.  Clinical application of transcriptional activators of bile salt transporters.

Authors:  Anna Baghdasaryan; Peter Chiba; Michael Trauner
Journal:  Mol Aspects Med       Date:  2013-12-12

7.  Nigramide J is a novel potent inverse agonist of the human constitutive androstane receptor.

Authors:  Yuichiro Kanno; Nobuaki Tanuma; Tomofumi Yatsu; Wei Li; Kazuo Koike; Yoshio Inouye
Journal:  Pharmacol Res Perspect       Date:  2014-01-26

8.  Binding Affinity via Docking: Fact and Fiction.

Authors:  Tatu Pantsar; Antti Poso
Journal:  Molecules       Date:  2018-07-30       Impact factor: 4.411

9.  DNA elements for constitutive androstane receptor- and pregnane X receptor-mediated regulation of bovine CYP3A28 gene.

Authors:  Mery Giantin; Jenni Küblbeck; Vanessa Zancanella; Viktoria Prantner; Fabiana Sansonetti; Axel Schoeniger; Roberta Tolosi; Giorgia Guerra; Silvia Da Ros; Mauro Dacasto; Paavo Honkakoski
Journal:  PLoS One       Date:  2019-03-25       Impact factor: 3.240

10.  CINPA1 is an inhibitor of constitutive androstane receptor that does not activate pregnane X receptor.

Authors:  Milu T Cherian; Wenwei Lin; Jing Wu; Taosheng Chen
Journal:  Mol Pharmacol       Date:  2015-03-11       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.